X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.120
-0.050 (-1.58%)
Nov 13, 2026, 4:00 PM EST - Market closed
X4 Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 16.96 | 35.11 | 2.56 | - | - | - | |
Revenue Growth | -50.08% | 1273.21% | -14.77% | - | - | - |
Cost of Revenue | 3.09 | 5.76 | 0.8 | - | - | - |
Gross Profit | 13.87 | 29.36 | 1.76 | - | - | - |
Selling, General & Admin | 26.78 | 38.52 | 61.52 | 35.51 | 27.02 | 24.7 |
Research & Development | 60.24 | 70.72 | 81.64 | 72.02 | 61.06 | 50.65 |
Operating Expenses | 87.02 | 109.24 | 143.16 | 107.52 | 88.08 | 75.35 |
Operating Income | -73.15 | -79.88 | -141.4 | -107.52 | -88.08 | -75.35 |
Interest Expense | -8.68 | -8.88 | -8.77 | -5.78 | -3.99 | -3.64 |
Interest & Investment Income | 7.89 | 4.58 | 5.77 | 4.58 | 0.22 | 0.01 |
Other Non Operating Income (Expenses) | 0.66 | 12.03 | 2.26 | 7.63 | -2.5 | 0.06 |
EBT Excluding Unusual Items | -73.28 | -72.16 | -142.14 | -101.09 | -94.35 | -78.92 |
Merger & Restructuring Charges | -7.24 | -7 | - | - | - | - |
Impairment of Goodwill | - | - | - | - | - | -9.76 |
Gain (Loss) on Sale of Assets | - | - | 105 | - | 0.51 | - |
Pretax Income | -80.52 | -79.16 | -37.14 | -101.09 | -93.84 | -88.68 |
Income Tax Expense | 0.01 | 0.04 | 0.31 | 0.08 | 0.03 | 0.02 |
Net Income | -80.52 | -79.2 | -37.45 | -101.17 | -93.87 | -88.7 |
Preferred Dividends & Other Adjustments | - | - | - | - | 2.55 | 13.94 |
Net Income to Common | -80.52 | -79.2 | -37.45 | -101.17 | -96.41 | -102.64 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 123 | 42 | 7 | 6 | 2 | 1 |
Shares Outstanding (Diluted) | 123 | 42 | 7 | 6 | 2 | 1 |
Shares Change | 660.42% | 531.04% | 13.08% | 179.91% | 146.71% | 28.25% |
EPS (Basic) | -0.66 | -1.87 | -5.59 | -17.07 | -45.53 | -119.59 |
EPS (Diluted) | -0.66 | -1.87 | -5.59 | -17.07 | -45.53 | -119.59 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -76.1 | -85.62 | -131.23 | -96.57 | -77.21 | -71.52 |
Free Cash Flow Per Share | -0.62 | -2.02 | -19.58 | -16.29 | -36.46 | -83.33 |
Gross Margin | 81.77% | 83.60% | 68.83% | - | - | - |
Operating Margin | -431.29% | -227.50% | -5529.96% | - | - | - |
Profit Margin | -474.74% | -225.56% | -1464.61% | - | - | - |
Free Cash Flow Margin | -448.68% | -243.84% | -5132.07% | - | - | - |
EBITDA | -71.38 | -78.61 | -140.61 | -107.1 | -87.57 | -74.85 |
EBITDA Margin | - | -223.87% | - | - | - | - |
D&A For EBITDA | 1.77 | 1.28 | 0.8 | 0.42 | 0.51 | 0.5 |
EBIT | -73.15 | -79.88 | -141.4 | -107.52 | -88.08 | -75.35 |
EBIT Margin | - | -227.50% | - | - | - | - |
Revenue as Reported | 16.96 | 35.11 | 2.56 | - | - | - |